First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Judd Klingerman's selected project will take him to Madrid, Spain, for six weeks this summer.
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
The state has for several years been moving toward competitive integrated employment, in which people with disabilities work ...
3d
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback